Examination about the efficacy and safety of abatacept iv in rheumatoid arthritis
Not Applicable
- Conditions
- Rheumatoid arthritis
- Registration Number
- JPRN-UMIN000019262
- Lead Sponsor
- Takarazuka city hospital
- Brief Summary
Rammission Rate at week 48 (as follow) DAS28ESR 34.5% SDAI 34.5% High disease activity patients got more efficacy response by abatacept therapy than others.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
patients with no MTX treatment past biological agents' user
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Clinical Remission Rate at week 48 Treatment reactivity by disease activity at week 48. Safety in this study period.
- Secondary Outcome Measures
Name Time Method modified total sharp score at week48 J-HAQ at week 48 Disease activity score